Phase I/II study of CTLA-4 inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors
| Autor: | S. Hu, David Savitsky, Olga Shebanova, M. Carini, E. Dow, T. Meniawy, Christopher D. Dupont, M. Lim, R.B. Stein, Ana M. Martín González, Charlotte Lemech, W. Ortuzar, Jennifer Buell, Hagop Youssoufian, Jermaine Coward |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Cervical cancer biology business.industry Hematology medicine.disease 03 medical and health sciences Cytotoxic T-lymphocyte Antigen 4 030104 developmental biology 0302 clinical medicine Phase i ii Oncology Refractory CTLA-4 030220 oncology & carcinogenesis Programmed cell death 1 Cancer research biology.protein Medicine In patient business |
| Zdroj: | Annals of Oncology. 29:viii417 |
| ISSN: | 0923-7534 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|